Wilmer Cutler Pickering Hale and Dorr advised Dyne Therapeutics, Inc. on the offering, and Cooley advised the underwriters. Dyne Therapeutics, Inc. (Nasdaq:DYN) announced the closing of...
Dyne Therapeutics’ $374.3 Million Common Stock Offering
Apellis Pharmaceuticals’ $475 Million Financing Agreement with Sixth Street
Wilmer Cutler Pickering Hale and Dorr advised Apellis Pharmaceuticals, Inc. on the deal, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Eose advised Sixth...
Dyne Therapeutics’ $345 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Dyne Therapeutics, Inc., and Cooley advised the underwriters. Dyne Therapeutics, Inc. (Nasdaq:DYN) (“Dyne”) announced the closing of an underwritten public offering...
Gemini Therapeutics’ Combination with Disc Medicine
Wilmer Cutler Pickering Hale and Dorr advised Gemini, while Goodwin Procter advised Disc Medicine. Fried, Frank, Harris, Shriver & Jacobson acted as counsel to SVB Securities...
Apellis’ Research Collaboration With Beam Therapeutics
Wilmer Cutler Pickering Hale and Dorr advised Apellis Pharmaceuticals on the deal. Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. (Nasdaq: BEAM), announced that they...